Pediatrix Medical Group, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Pediatrix reported Q3 2026 net revenue of $501.4M (+1.7% YoY) and net income of $47.0M ($0.59 diluted EPS), compared to $71.7M ($0.84 EPS) in Q3 2025; Adjusted EPS of $0.72 exceeded prior-year $0.67. Nine-month Adjusted EBITDA reached $220.1M (+4.9% YoY) on $1.465B revenue (+3.2% YoY). Full-year 2026 Adjusted EBITDA guidance: $290–$300M. Cash decreased from $375.2M (Dec 2025) to $311.9M; company repurchased $83.0M shares in Q3 and maintains $578M debt ($400M Senior Notes, $178M Term A Loan).
Why this rating
Modest revenue growth (1.7% Q3, 3.2% YTD) with mixed underlying dynamics—acquisitions offset divestitures, same-unit revenue near flat. Q3 net income declined 34% YoY despite Adjusted EPS growth, driven by prior-year $20.9M divestment gain. Guidance reaffirmed but represents incremental improvement; cash burn ($83M buyback) offsets modest EBITDA gains. Routine quarterly update for $900M company.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.